Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3055-3070

  Liu, Youhong ^a   Chen, Lin ^a   Gong, Zhicheng ^a   Shen, Liangfang ^a   Kao, Chinghai ^b   Hock, Janet M ^c   Sun, Lunquan ^a   Li, Xiong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Adenovirus; Apoptosis; Gene therapy; Statins; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; CELL RECEPTOR; CHOLESTEROL; DEATH RECEPTOR 4; INTEGRIN; MEVINOLIN; ONCOLYTIC ADENOVIRUS; PROSTATE RESTRICTED REPLICATION COMPETENT ADENOVIRAL VECTOR; PROTEIN CAR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CLMP PROTEIN, HUMAN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR LIKE MEMBRANE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXPLORATORY RESEARCH; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID RAFT; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT; VIRUS REPLICATION; BIOSYNTHESIS; CELL MEMBRANE; DEFICIENCY; DEPENDOPARVOVIRUS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHOLESTEROL; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTEGRINS; LOVASTATIN; MALE; MEMBRANE MICRODOMAINS; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923272431     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3073     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. Thomas CE, Ehrhardt A and Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nature reviews Genetics. 2003; 4(5):346-358.
3. Green NK and Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer gene therapy. 2002; 9(12):1036-1042.
4. Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jimenez JA, Gardner TA, Jeng MH and Kao C. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer research. 2005; 65(5):1941-1951.
5. Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L and Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Molecular therapy: the journal of the American Society of Gene Therapy. 2002; 6(3):415-421.
6. Ahn M, Lee SJ, Li X, Jimenez JA, Zhang YP, Bae KH, Mohammadi Y, Kao C and Gardner TA. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer gene therapy. 2009; 16(1):73-82.
7. Jimenez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C and Gardner TA. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer gene therapy. 2010; 17(3):180-191.
8. Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH and Kao C. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(18 Pt 1):5463-5473.
9. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH and Kao C. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(1):291-299.
10. Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD and Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 2011; 133(2):221-238.
11. Wang S and El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003; 22(53):8628-8633.
12. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997; 277(5327):815-818.
13. Prabhakar BS, Mulherkar N and Prasad KV. Role of IG20 splice variants in TRAIL resistance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(2):347-351.
14. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature medicine. 1999; 5(2):157-163.
15. Murtola TJ, Tammela TL, Lahtela J and Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007; 16(11):2226-2232.
16. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC and Giovannucci E. Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute. 2006; 98(24):1819-1825.
17. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A and Farris PE. Statins and prostate cancer risk: a case-control study. American journal of epidemiology. 2005; 162(4):318-325.
18. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB and Green JE. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003; 24(3):453-459.
19. Sivaprasad U, Abbas T and Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Molecular cancer therapeutics. 2006; 5(9):2310-2316.
20. Li YC, Park MJ, Ye SK, Kim CW and Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol- depleting agents. The American journal of pathology. 2006; 168(4):1107-1118; quiz 1404-1105.
21. Chan DY, Chen GG, Poon WS and Liu PC. Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. Journal of neuro-oncology. 2008; 86(3):273-283.
22. Holstein SA and Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Molecular cancer therapeutics. 2001; 1(2):141-149.
23. Werner M, Sacher J and Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. British journal of pharmacology. 2004; 143(6):715-724.
24. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993; 73(2):309-319.
25. Wang C, Yoo Y, Fan H, Kim E, Guan KL and Guan JL. Regulation of Integrin beta 1 recycling to lipid rafts by Rab1a to promote cell migration. The Journal of biological chemistry. 2010; 285(38):29398-29405.
26. Del Pozo MA. Integrin signaling and lipid rafts. Cell cycle. 2004; 3(6):725-728.
27. Ashbourne Excoffon KJ, Moninger T and Zabner J. The coxsackie B virus and adenovirus receptor resides in a distinct membrane microdomain. Journal of virology. 2003; 77(4):2559-2567.
28. Marconi M, Ascione B, Ciarlo L, Vona R, Garofalo T, Sorice M, Gianni AM, Locatelli SL, Carlo-Stella C, Malorni W and Matarrese P. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. Cell death & disease. 2013; 4:e863.
29. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E and Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Molecular and cellular biology. 2006; 26(19):7046-7055.
30. Bollinger CR, Teichgraber V and Gulbins E. Ceramide-enriched membrane domains. Biochimica et biophysica acta. 2005; 1746(3):284-294.
31. Yamazaki S, Iwama A, Morita Y, Eto K, Ema H and Nakauchi H. Cytokine signaling, lipid raft clustering, and HSC hibernation. Annals of the New York Academy of Sciences. 2007; 1106:54-63.
32. Li PL, Zhang Y and Yi F. Lipid raft redox signaling platforms in endothelial dysfunction. Antioxidants & redox signaling. 2007; 9(9):1457-1470.
33. Chazal N and Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiology and molecular biology reviews: MMBR. 2003; 67(2):226-237, table of contents.
34. Gajate C, Gonzalez-Camacho F and Mollinedo F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochemical and biophysical research communications. 2009; 380(4):780-784.
35. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochimica et biophysica acta. 2008; 1785(2):182-206.
36. Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL and Cheng JX. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell metabolism. 2014; 19(3):393-406.
37. Krycer JR and Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochimica et biophysica acta. 2013; 1835(2):219-229.
38. Martirosyan A, Clendening JW, Goard CA and Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC cancer. 2010; 10:103.
39. Alberts AW. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology. 1990; 77 Suppl 4:14-21.
40. Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. The Journal of clinical investigation. 2005; 115(4):959-968.
41. Werner B, Dittmann S, Funke C, Uberla K, Piper C, Niehaus K, Horstkotte D and Farr M. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation research: official journal of the European Histamine Research Society [et al]. 2014; 63(4):267-276.
42. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L and Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Molecular cancer therapeutics. 2007; 6(9):2591-2599.
43. Lim SC, Duong HQ, Choi JE, Lee TB, Kang JH, Oh SH and Han SI. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis. 2011; 32(5):723-731.
44. Mollinedo F and Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2006; 9(1-2):51-73.
45. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC and Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer research. 1991; 51(14):3753-3761.
46. Nikkhah M, Strobl JS, Schmelz EM and Agah M. Evaluation of the influence of growth medium composition on cell elasticity. Journal of biomechanics. 2011; 44(4):762-766.
47. Wang Y, Gangeswaran R, Zhao X, Wang P, Tysome J, Bhakta V, Yuan M, Chikkanna-Gowda CP, Jiang G, Gao D, Cao F, Francis J, Yu J, Liu K, Yang H, Zhang Y, et al. CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. The Journal of clinical investigation. 2009; 119(6):1604-1615.
48. Irish JM, Kotecha N and Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature reviews Cancer. 2006; 6(2):146-155.